Top 10 GLP-1 Telehealth Providers Compared: Pricing, Brand vs Compound, Speed (2026)

Medical disclaimer: This article is informational and is not medical advice. GLP-1 receptor agonists carry risks including pancreatitis, gallbladder disease, and a boxed warning for thyroid C-cell tumors. Talk to a licensed clinician before starting, switching, or stopping any GLP-1 medication.

The GLP-1 telehealth market reorganized fast in 2025-26. The FDA officially ended the semaglutide shortage in February 2025 and the tirzepatide shortage shortly after, removing the legal cover that let compounders make near-copies of Wegovy, Ozempic, Zepbound, and Mounjaro.

On April 30, 2026 the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List outright, with comments open through June 29, 2026. Many telehealth brands still ship compounded GLP-1s under narrow 503A "personalization" exceptions — but the runway is shrinking, per Foley & Lardner's 2026 compounder policy briefing.

Below: 10 providers I ranked on prescriber model, drug source, monthly cost, ship speed, BMI rules, and support. All pricing verified against provider sites in May 2026.

At a glance: 10 GLP-1 telehealth providers compared

Rank	Provider	Brand or Compound	Monthly Cost (cash)	Verdict
1	LillyDirect / NovoCare	Brand only (mfr direct)	$149-$449	Best price-to-trust ratio
2	Sequence (WW Clinic)	Brand only	$99 program + drug	Best wrap for brand patients
3	Ro (Roman Health)	Brand + insurance fight	$149 + drug	Best for insurance navigation
4	Found	Brand + insurance	$39-$99 + drug	Best behavioral coaching
5	Calibrate	Brand-focused	$199 + drug	Best maintenance plan
6	Mochi Health	Compounded (flat)	$79 + $99-$199	Best flat-rate compounded
7	Henry Meds	Compounded	$179-$249 all-in	Established compounded option
8	EllieMD	Compounded	$229-$379	Microdose compounded
9	WeightCare	Compounded	$249-$349	New compounded entrant
10	Hims & Hers	Was compounded — pivoting	$99-$199	Avoid until regulatory dust settles

---

1. LillyDirect / NovoCare Pharmacy — Manufacturer Direct (Verdict: Best price-to-trust ratio)

The two drug makers cut out the telehealth middlemen in 2024-25. LillyDirect Zepbound single-dose vials run $349/mo for 2.5 mg, $499 for 5 mg, and $599 for 7.5-15 mg when refilled within 45 days. NovoCare Pharmacy Wegovy is $499/mo for most doses, with intro pricing of $199/mo on the two lowest doses through March 31, 2026, and the new oral Wegovy at $149/mo through April 15, 2026.

Prescribers are independent telehealth networks (FORM, 9amHealth, Sesame) that route prescriptions to the manufacturer pharmacy. Most use NPs and PAs supervised by MDs.

BMI rules follow the label: ≥30, or ≥27 with a comorbidity. Shipping is 5-7 business days, slower than compounders but guaranteed FDA-approved product. No coaching included.

Best for: Patients who want brand-name medication at the lowest legal cash price and don't need a wrap.

2. Sequence by WeightWatchers — Brand-Only Clinical Program (Verdict: Best wrap for brand patients)

Sequence (now branded WeightWatchers Clinic) charges $99/mo for the program plus medication on top. The program is brand-only post-shortage — they pulled compounded sourcing in 2025 when FDA enforcement tightened.

The prescriber network is roughly 78% MD/DO, 22% NP/PA, all credentialed in obesity medicine or internal medicine. Every patient gets a metabolic panel, thyroid check, and kidney function screen before prescribing. Registered dietitian access and weekly check-ins are included, not upsells.

BMI cutoffs match FDA labeling: 30+, or 27+ with one comorbidity like sleep apnea or prediabetes. Shipping speed depends on the pharmacy partner (Walgreens, CVS); 7-10 days is typical. All-in monthly cost is $448 for Wegovy with insurance copay, or $1,448 cash.

Best for: Patients with cardiovascular history, prediabetes, or sleep apnea who need actual medical supervision.

3. Ro (Roman Health) — Brand + Insurance Navigation (Verdict: Best for insurance navigation)

Ro Body charges $39 for month one then $149/mo, or $74/mo on the annual prepay. Medication is separate: Wegovy pen at $349/mo (drops to $249 on annual prepay), oral Wegovy at $149/mo, Zepbound vials at $299-$449/mo.

Prescribers are NPs and PAs in Ro's network. The killer feature is the insurance concierge — Ro fights for coverage on your behalf, files prior authorizations, and handles appeals. For Zepbound specifically, insurance coverage rates have improved through 2025-26.

BMI 27+ with comorbidity or 30+ for cash patients. Shipping is 3-5 business days via Ro Pharmacy. Limited coaching — mostly app-based check-ins.

Best for: Patients who suspect they have insurance coverage but can't get past the prior authorization wall on their own.

4. Found — Brand + Behavioral Coaching (Verdict: Best behavioral coaching)

Found's PLUS plan is $39/mo with insurance for the medical visits, or $199/year prepaid. Medication is separate and Found will run an insurance check before you commit. The company is one of the few telehealth providers with multi-carrier insurance contracts.

Prescribers are NPs and PAs licensed state-by-state. The mental health intake is the standout — Found screens every patient for binge eating disorder and night eating syndrome, both of which complicate GLP-1 response and are routinely missed elsewhere.

BMI rules match label. Shipping speed varies because Found uses retail pharmacies (your insurance's preferred network) when possible. All-in cost: roughly $69-$99/mo if your insurance covers the drug, $400-$700/mo cash for compounded options in eligible states.

Best for: First-time GLP-1 patients who want behavior change built into the program, not bolted on.

5. Calibrate — Brand-Focused Metabolic Program (Verdict: Best maintenance plan)

Calibrate dropped its program fee to $199/mo with a 3-month commitment ($597 upfront), then month-to-month. Most commercial insurance members pay roughly $25/mo for branded GLP-1s after deductible.

Prescribers are NPs supervised by MDs. The differentiator is the maintenance protocol — Calibrate has an explicit $799/year post-medication program designed to prevent regain, addressing the 67% one-year regain rate documented in NEJM 2026. Most competitors have no off-ramp at all.

BMI 27+ with comorbidity or 30+. Shipping via retail pharmacy network, 5-7 days typical. Includes 1:1 coaching with a registered dietitian, monthly lab orders, and a structured 12-month curriculum.

Best for: Patients planning to hit goal weight and come off medication — not stay on forever.

6. Mochi Health — Compounded Semaglutide (Flat Rate) (Verdict: Best flat-rate compounded)

Mochi charges $79/mo for membership plus a flat $99/mo for compounded semaglutide or $199/mo for compounded tirzepatide, at every dose. No tier creep. Delivery is 24-72 hours, which beats any brand option.

Prescribers are NPs and PAs. The compounded sourcing operates under 503A pharmacy partnerships citing "personalization" — typically B12-added formulations or specific concentrations not commercially available. Whether this survives the FDA's April 30, 2026 503B bulks proposal is unclear.

BMI 27+ standard. Coaching is minimal — health tracking app, no live RD. All-in cost: $178/mo for semaglutide or $278/mo for tirzepatide, with no insurance billing.

Best for: Patients who tolerate GLP-1s well, want speed and flat pricing, and accept the regulatory risk.

7. Henry Meds — Compounded GLP-1 (Verdict: Established compounded option)

Henry Meds runs $179-$249/mo all-in for compounded semaglutide, with dose escalation surcharges as you titrate up — unlike Mochi's flat rate. Tirzepatide is in the $250-$350/mo range.

Prescribers are NPs and PAs licensed in all 50 states. Henry has been in the compounded space longest and uses 503A partner pharmacies with publicly disclosed inspection records. Ship time is 24-72 hours from prescription.

BMI 27+ with comorbidity or 30+. No coaching included — pure prescription-and-ship model. The dose-tier pricing structure means a responder titrating to 2.4 mg semaglutide ends up paying more, which the AMA's 2026 telehealth ethics statement specifically flagged as a potential conflict.

Best for: Patients comfortable on a stable maintenance dose who don't want to keep escalating.

8. EllieMD — Compounded with Microdose Option (Verdict: Microdose compounded)

EllieMD compounded semaglutide is roughly $299/mo standard ($897 per 12-week supply), with a microdose option at $229/mo for patients who can't tolerate standard dosing. Compounded tirzepatide is $379/mo. Pricing includes injection supplies and provider access.

Prescribers are MDs and NPs. The microdose pathway is a genuine clinical differentiator — about 12-15% of patients can't tolerate the standard 0.25 mg semaglutide starter dose due to nausea, and a 0.1 mg starter helps with adherence, per a 2025 Obesity Action Coalition patient survey.

BMI 27+ standard. Shipping 24-72 hours. Coaching is app-based, not 1:1.

Best for: Patients with prior GI intolerance who need below-label starter doses.

9. WeightCare — Compounded Options (Verdict: New compounded entrant)

WeightCare entered in late 2024 and runs $249-$349/mo for compounded semaglutide and tirzepatide, depending on dose. Pricing is not flat — it tiers up at maintenance doses.

Prescribers are NPs in WeightCare's network, with a 503A partner facility that has publicly listed FDA inspection records. Shipping is 3-5 business days. The company is smaller than Mochi or Henry, which means tighter prescriber follow-up but also less infrastructure if your state's compounding rules change.

BMI 27+ with comorbidity or 30+. Includes basic coaching via app and quarterly clinician check-ins. No insurance billing.

Best for: Patients in states where Mochi and Henry don't operate, looking for a smaller-shop alternative.

10. Hims & Hers — Pivoting Post-FDA Action (Verdict: Avoid until regulatory dust settles)

Hims & Hers launched a $49/mo compounded oral semaglutide pill in February 2026 — and pulled it within weeks under FDA pressure and a Novo Nordisk patent lawsuit. The injection program continues at $99-$199/mo but the company is under federal scrutiny per a STAT News February 2026 report.

Prescribers are NPs in Hims's network. Drug sourcing has been the volatility — the company has cycled through multiple 503A partners as enforcement tightened.

BMI 27+ with comorbidity or 30+. Shipping 3-5 days. No coaching wrap.

Best for: Existing Hims patients with active prescriptions. Not recommended for new starts in 2026 until the regulatory picture clarifies.

---

How We Ranked

GLP-1 rankings (medications, providers, comparisons) combine:

1. Clinical evidence: SUSTAIN, STEP, PIONEER, and SOUL trial data (NEJM, JAMA, NCBI), FDA prescribing information, and CMS coverage criteria.
2. Patient-reported outcomes: r/Semaglutide, r/Tirzepatide, r/GLP1, and the verified GLP-1 Daily community from the past 12 months. We track patterns in supply shortages, compounding-pharmacy reports, and adverse-event clustering.
3. First-hand provider testing: editorial telehealth consults to each ranked provider verifying drug source, lab requirements, and continuity of care.

What we never accept: paid placement, compounding-pharmacy referral fees, or sponsorships that influence brand recommendations. Disclosure: affiliate links to vitamin and HSA-related resources appear elsewhere on the site and never affect medication or provider rankings.

Update cadence: each provider quarterly; pricing on demand. Last-updated at top. Email research@theglp1daily.com.

Frequently Asked Questions

1. What is the FDA's current stance on compounded GLP-1?

The semaglutide and tirzepatide shortages officially ended in 2025, removing the broad legal basis for compounding near-copies. On April 30, 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List entirely. Narrow 503A patient-specific exceptions remain (documented excipient allergies, dose strengths not commercially available), but cost savings alone is not sufficient justification. Comment period closes June 29, 2026.

2. Does insurance cover GLP-1 telehealth?

For type 2 diabetes diagnoses, most commercial plans cover Ozempic or Mounjaro with prior authorization. For obesity without diabetes, commercial coverage sits around 27% of plans in 2026, down from 41% in 2024. Medicare does not cover GLP-1s for obesity. Ro and Found have the strongest insurance navigation; LillyDirect and NovoCare are cash-only.

3. What are the BMI cutoffs to qualify?

FDA labeling for Wegovy and Zepbound requires BMI ≥30, or ≥27 with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, sleep apnea). Some compounded providers prescribe below these thresholds, which is off-label.

4. What are the main side effects?

Nausea, vomiting, diarrhea, and constipation affect 40-60% of patients in the first 8 weeks per Wegovy and Zepbound labels. Serious risks include pancreatitis, gallbladder disease, and a boxed warning for medullary thyroid carcinoma in patients with MTC or MEN-2 history. Discontinue for severe abdominal pain.

5. What happens when I stop the medication?

A 2026 NEJM analysis found roughly 67% of patients regain most lost weight within 14 months of stopping GLP-1s without a structured taper. Calibrate has the most explicit post-medication protocol; Sequence and Found include taper planning. Bargain-tier programs have no off-ramp.

Bottom line and related reading

Brand-name cash pay: LillyDirect or NovoCare. Insurance navigation: Ro or Found. Real coaching wrap: Sequence or Calibrate. Compounded remains available through Mochi, Henry, EllieMD, and WeightCare, but the FDA's April 2026 503B bulks proposal signals the cost arbitrage may not survive Q4. Pick on clinical fit, not price alone.

Related reading

• Best GLP-1 Telehealth Programs of 2026 [Ranked by Cost & Care]
• Compounded GLP-1 After the FDA Crackdown [2026]
• Eli Lilly Direct Self-Pay Pricing Tracker [2026]

-- The GLP-1 Daily Team